$IBRX-Here is the breakdown of the PSS post and the best way to understand it. 1. The "Special Forces" Analogy (The Clinical Edge) The Message: Most cancer treatments (like chemo) are "carpet bombs" that damage everything. ANKTIVA is "Special Forces" it specifically recruits and arms NK Cells and Killer T-Cells. Key Stat: Highlight the Hazard Ratio (HR) of 0.4 for duration of response. This means ANKTIVA-treated patients have a 60% lower risk of cancer returning compared to the standard of care. 2. The "Leonardo" Connection (The Industrial Edge) The Message: PSS is "connecting the dots" between the science and the machine. The NANT Leonardo AI-robotic platform is the factory that makes the "Special Forces." The 1:10 Shift: This is your strongest data point. 1:10 donor-to-dose ratio is no longer a theory it’s a robotic reality that scales globally. 3. Global Geopolitical Signaling The Message: PSS is signaling that while the US regulatory path is a "fight," the rest of the world (starting with the March 15 Saudi Launch) is already embracing the future. The "Enlightenment": He is essentially saying the "BioShield" isn't just a drug; it’s a global infrastructure for cancer care. 4. European Validation (EAU26) The timing of this post, coinciding with the EAU26 (European Association of Urology) congress in London, is a signal of geographical expansion. Global Standard: He is signaling that European clinicians now "understand" that ANKTIVA is not just a secondary treatment but a foundational "Special Forces" unit that can cure cancer by activating the innate and adaptive immune systems simultaneously. 5. Slide in the background The slide in the background of his post emphasizes Key Mechanisms: Long-term Memory: One of the most important signals here is "Promotes durable immune memory without exhaustion." The Message to Shorts: This is a direct counter-narrative to those betting on short-term results. PSS is signaling that ANKTIVA creates a permanent internal defense system (Memory T cells), which is the key to the "curative" potential he mentions. THE ENLIGHTENMENT HAS BEGUN. Dr. Patrick Soon-Shiong (@DrPatSoonShiong) just validated the "Leonardo" robotic thesis. This isn't just a biotech story; it's an industrial revolution. Special Forces: ANKTIVA recruits the elite killers (NK & T-cells) to seek and destroy, while ignoring "Tregs" (the tumor’s shield). Leonardo Robotics: The AI-driven backbone enabling the 1:10 dose yieldand 90% COGS reduction. Global Access: "Certain countries" are already moving. The Saudi launch on March 15 is just the start.Standard of Care is being disrupted in real-time. #IBRX #ANKTIVA #Immunotherapy #ShortSqueeze